Advaxis, Merck to combine immunotherapies for prostate cancer
This article was originally published in Scrip
Executive Summary
Advaxis jumped 23.1% to $4 per share on 25 August after the company announced a second partnership to test its immunotherapy platform in combination with a programmed cell death-1 (PD-1) inhibitor, the Merck & Co biologic pembrolizumab (MK-3475).
You may also be interested in...
Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost
Advaxis is developing – now with help from partner Amgen – a personalized immunotherapy strategy with each patient's cancer vaccine based on their own tumor's specific neoepitopes.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.